Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Tesla Semi Rollout Begins at Nevada Factory 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
OpenAI Agent Breaches Australia Medicare Data Portal 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
H&M Q3 Profit Beats Estimates as Margins Improve 
Apple Extends Qualcomm Patent Licensing Deal 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
SMBC Eyes 20% VPBank Stake in Vietnam Expansion 
SoftBank Raises $11.1 Billion in Bond Sale to Fund OpenAI Investment 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
McDonald’s Sees Flat Traffic, Sticky Inflation as New Normal 
Add as a preferred source on Google
Novo Nordisk has agreed to pay up to €1.165 billion ($1.37 billion) to license drug-delivery technology from Swedish biotechnology company Nanexa, potentially paving the way for longer-lasting obesity and diabetes treatments that require fewer injections.
The exclusive global licensing agreement gives Novo Nordisk access to Nanexa’s PharmaShell platform, a drug-delivery technology designed to enable the controlled release of medicines over extended periods. The partnership will cover as many as five development programs focused on obesity, type 2 diabetes and other cardiometabolic diseases.
If successful, the technology could allow some Novo Nordisk treatments that are currently administered weekly to be given once a month or even once every three months. Longer dosing intervals could improve convenience for patients and potentially strengthen Novo Nordisk’s position in the rapidly expanding obesity and diabetes drug markets.
Under the agreement, Novo Nordisk will pay Nanexa up to €615 million through upfront payments and development and regulatory milestones. Additional payments tied to commercial sales milestones could bring the total value of the deal to €1.165 billion.
Nanexa will also be entitled to low-single-digit royalties on worldwide net sales of products developed using its PharmaShell technology.
Novo Nordisk will take responsibility for the global development and commercialization of treatments arising from the partnership. The Danish pharmaceutical company is already one of the world’s leading developers of obesity and diabetes medicines, making longer-acting formulations an important potential area for expanding its cardiometabolic portfolio.
For Nanexa, the licensing agreement provides a major opportunity to deploy its drug-delivery platform across multiple large-scale development programs backed by Novo Nordisk’s global clinical and commercial infrastructure.
The deal comes as pharmaceutical companies increasingly explore longer-acting drug formulations to make chronic treatments easier for patients to use. In obesity and type 2 diabetes, where injectable therapies may need to be taken for extended periods, reducing dosing frequency could become an important factor in future treatment development.
